Free Trial

Unicycive Therapeutics Q3 2023 Earnings Report

Unicycive Therapeutics logo
$0.69 -0.01 (-1.36%)
(As of 12:51 PM ET)

Unicycive Therapeutics EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.13
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Unicycive Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Unicycive Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Do this Before Elon’s Reveal on January 22nd (Ad)

Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.

I urge you to watch this video now.

Unicycive Therapeutics Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.
See More Unicycive Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Unicycive Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unicycive Therapeutics and other key companies, straight to your email.

About Unicycive Therapeutics

Unicycive Therapeutics (NASDAQ:UNCY), a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

View Unicycive Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings